|
Market Closed -
Nasdaq
00:00:00 25/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 11.72 USD | -1.43% |
|
-6.98% | -25.26% |
Company Valuation: Monte Rosa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 949.7 | 368.3 | 282.8 | 426.4 | 1,021 | 999.9 | - | - |
| Change | - | -61.22% | -23.21% | 50.74% | 139.48% | -2.07% | - | - |
| Enterprise Value (EV) | 603.6 | 105.5 | 50.43 | 54.22 | 1,021 | 999.9 | 999.9 | 999.9 |
| Change | - | -82.52% | -52.19% | 7.5% | 1,783.24% | -2.07% | 0% | 0% |
| P/E | -6.9x | -3.31x | -2.15x | -7.08x | -34.1x | -7.8x | -6.18x | -7.04x |
| PBR | 2.75x | 1.32x | 1.58x | 1.91x | - | - | - | - |
| PEG | - | 0.1x | -0.1x | 0.1x | 0.6x | -0x | -0.2x | 0.6x |
| Capitalization / Revenue | - | - | - | 5.64x | 8.26x | 15.2x | 17.5x | 9.81x |
| EV / Revenue | - | - | - | 0x | 0x | 15.2x | 17.5x | 9.81x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -5.84x | -4.62x | -5.01x |
| EV / FCF | -0x | -0x | -0x | 0x | -0x | -11.9x | -14.3x | 31.9x |
| FCF Yield | -7.28% | -28.6% | -22.2% | 8.91% | -2.69% | -8.41% | -7% | 3.13% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | -1.504 | -1.896 | -1.665 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 75.62 | 123.7 | 65.89 | 57.07 | 101.9 |
| EBITDA | -70.75 | -108.6 | -137.1 | -72.99 | - | - | - | - |
| EBIT 1 | -72.88 | -112.4 | -143.3 | -81.11 | -54.21 | -171.2 | -216.4 | -199.7 |
| Net income 1 | -73.96 | -108.5 | -135.4 | -72.7 | -38.63 | -151.9 | -201.2 | -188.3 |
| Net Debt | -346.1 | -262.8 | -232.4 | -372.1 | - | - | - | - |
| Reference price 2 | 20.42 | 7.61 | 5.65 | 6.94 | 15.68 | 11.72 | 11.72 | 11.72 |
| Nbr of stocks (in thousands) | 46,506 | 48,399 | 50,062 | 61,436 | 65,118 | 85,313 | - | - |
| Announcement Date | 29/03/22 | 16/03/23 | 14/03/24 | 20/03/25 | 17/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.8x | - | - | - | 1B | |
| 33.31x | 5.98x | 17.9x | 0.97% | 48.01B | |
| 35.42x | 3.39x | 14.64x | -.--% | 45.27B | |
| 47.15x | 5.46x | 29.88x | -.--% | 40.93B | |
| -20.54x | 221.64x | -22.17x | -.--% | 42.84B | |
| 26.85x | 7.74x | 19.93x | 0.42% | 29.6B | |
| 35.29x | 5.79x | 26.32x | -.--% | 17.32B | |
| 25.91x | 2.22x | 9.63x | 1.03% | 15.34B | |
| -59.05x | 9.67x | 236.13x | -.--% | 14.84B | |
| Average | 12.95x | 32.74x | 41.53x | 0.3% | 28.35B | |
| Weighted average by Cap. | 20.27x | 41.97x | 25.55x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GLUE Stock
- Valuation Monte Rosa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
